YONGIN, South Korea, Aug. 28, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Thailand Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial...
Hence then, the article about gc biopharma submits ind to begin phase 3 clinical trial for barycela in thailand was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma submits IND to begin Phase 3 Clinical Trial for BARYCELA in Thailand )
Also on site :
- Marjorie Taylor Greene: UFC fights don't belong on White House lawn
- REI’s ‘Tiny But Mighty’ $18 Waist Pack Is ‘Perfect for Travel, Exercise, and Adventure’
- Goldman nets a big payday for SpaceX IPO. Plus, what drove our winners and losers this week